Impact of Peanut Consumption on Stress, Immune Function, Inflammation, and Cardiovascular Health in High-Stress Individuals
8. September 2026 aktualisiert von: USDA, Western Human Nutrition Research Center
Effects of Peanut Consumption on Physiological and Psychosocial Stress, Circulating Immune Cell Status, Markers of Inflammation and Cardiovascular Disease Risk, and Gastrointestinal Health in High-Stress Individuals
The purpose of this research is to determine whether peanut consumption improves indicators of cardiovascular disease (CVD) risk in human subjects following the consumption of study foods.
Studienübersicht
Status
Rekrutierung
Intervention / Behandlung
Detaillierte Beschreibung
The overall goal of the proposed study is to determine whether peanut consumption improves indices of cardiovascular disease (CVD) risk in human subjects with high levels of perceived chronic stress.
Chronic stress is a growing public health concern and is associated with adverse health outcomes, including CVD.
Stress, experienced when a person feels that environmental, physiological, or psychosocial demands tax or exceed their adaptive capacity, triggers a coordinated response from the sympathetic nervous system (SNS) and hypothalamic- pituitary- adrenal (HPA) axis increasing blood pressure, driving systemic inflammation, and affecting the immune system by accelerating the output of disease-promoting immune cells from bone marrow.
Studientyp
Interventionell
Einschreibung (Geschätzt)
70
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Ellen Bonnel, PhD
- Telefonnummer: 530-752-4184
- E-Mail: elbonnel@ucdavis.edu
Studieren Sie die Kontaktsicherung
- Name: Ione Summers, BSc
- Telefonnummer: 530-754-8544
- E-Mail: iosummerssteffes@ucdavis.edu
Studienorte
-
-
California
-
Davis, California, Vereinigte Staaten, 95616
- Rekrutierung
- Western Human Nutrition Research Center
-
Kontakt:
- Ellen Bonnel, PhD
- Telefonnummer: 530-752-4184
- E-Mail: elbonnel@ucdavis.edu
-
Kontakt:
- Ione Summers, B.S.
- Telefonnummer: 530-754-8544
- E-Mail: iosummerssteffes@ucdavis.edu
-
Hauptermittler:
- Ryan Snodgrass, PhD
-
Unterermittler:
- Danielle Lemay, PhD
-
Unterermittler:
- Mary Kable, PhD
-
Unterermittler:
- Kevin Laugero, PhD
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Males and females
- 18-65 years old
- BMI ≥ 18.5 kg/m2 and ≤ 39.9 kg/ m2
- Recruitment will be based on Perceived Stress Scale - 4 (PSS-4) score
Exclusion Criteria:
- Less than 18 and over 65 years old
- Pregnant or lactating women
- Adults who rely on prescription medication that may influence study variables, apart from birth control
- BMI < 18.5 kg/m2 and > 39.9 kg/m2
- Smokers who currently use tobacco- or marijuana-containing products including e-cigarettes, vape pens, pod mods, tanks, and electronic nicotine delivery devices (ENDS)
- Habitual consumption of nuts, nut butters, nut powders, nut side dishes, nut bars or other nut products
- Known food allergies (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame, corn) due to samples not prepared in a hypoallergenic environment
- Currently living in close contact with individuals who have an allergy to peanuts, in order to avoid exposing these individuals to an allergen
- Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist
Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to:
- Diabetes mellitus, cardiovascular disease, cancer, gastrointestinal disorders, kidney disease, liver disease, bleeding disorders, asthma, autoimmune disorders, hypertension, osteoporosis
- Recent minor surgery (within 4 weeks) or major surgery (within 16 weeks)
- Known gallbladder disease or history of cholecystectomy
- History of gastrointestinal surgery, including gastric bypass surgery or resection
- Diagnosis of irritable bowel syndrome
- Recent antibiotic therapy (within 4 weeks)
- Recent hospitalization (within 4 weeks)
- Current participation in another research study
- Has HIV/AIDS, hepatitis, or another disease that affects the immune system
- Gives regular blood donations and is unwilling to stop during the study
- Blood Pressure ≥ 140 mmHg systolic or 90 mmHg diastolic
- Current diagnoses of an eating disorder (ex. anorexia, bulimia, etc.)
- High - very high triglyceride levels: ≥ 300 mg/dL
- Adults who are unable to consent, individuals who are not yet adults (infants, children and teenagers), pregnant women and prisoners will be excluded from participation in the study
- Participants who are unwilling to collect and transport urine, stool and saliva samples
- Abnormal hemoglobin and/or hematocrit levels
- Abnormal liver function (defined as liver enzymes that are >200% of upper limit (ALT upper limit is 43 U/L or Aspartate transaminase (AST) upper limit is 54 U/L)
- Unwillingness to discontinue probiotic, prebiotic, fiber, or other supplements (except RDA-level vitamin and mineral supplements) during the study
- Unwilling to consume study foods
- Alcohol consumption > 20 g/day
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Peanut Intervention followed by corn chips Intervention
Participants will be asked to consume 42g of peanuts with skin daily for 4 weeks.
Following a 4-week washout, the participant will then be asked to consume 45g of corn chips daily for 4 weeks.
|
42g roasted salted peanuts with skins consumed daily
Corn chips (45g)
|
|
Experimental: Corn chip Intervention followed by Peanut Intervention
The participant will be asked to consume 45g of corn chips daily for 4 weeks.
Following a 4-week washout, the participant will be then asked to consume 42g of peanuts with skin daily for 4 weeks.
|
42g roasted salted peanuts with skins consumed daily
Corn chips (45g)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in psychosocial stress over time
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
The PSS-10 will be administered 4 times during the study. The 10-item Perceived Stress Scale (PSS-10) is a validated, standard instrument used to assess subjective perceptions of chronic psychological stress (i.e., excessive demands, insufficient coping resources, and a perceived lack of control). The minimum score is 0 and the maximum score is 40. Higher scores indicate greater severity of psychosocial stress. |
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of allostatic load following dietary interventions
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Before and after each intervention, cumulative physiological stress load, also referred to as allostatic load (AL), will be calculated.
AL will be derived from 12-h overnight urinary cortisol, norepinephrine, and epinephrine levels (corrected for urinary creatinine levels), resting systolic and diastolic blood pressure, and overnight fasted waist-to-hip ratio, fasting serum levels of high-sensitivity C-reactive protein (hs-CRP), cholesterol, HDL-cholesterol, fasting plasma dehydroepiandrosterone sulfate (DHEA-S), and whole blood glycohemoglobin (HbA1c).
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of monocyte gene expression
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Total monocytes isolated from human peripheral blood mononuclear cells (PBMCs) at baseline and post-intervention will be collected, and their global gene expression will be analyzed by ribonucleic acid (RNA) sequencing.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of cytokine and interferon production in PBMCs
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Monocytes isolated from human peripheral blood mononuclear cells (PBMCs) will be challenged with and without toll-like receptor ligands to assess cytokine and interferon production in low- and high-stress subjects at baseline and after intervention.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of cytotoxicity of peripheral natural killer cells
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
The cytotoxicity of peripheral natural killer (NK) cells isolated from subject's peripheral blood mononuclear cells (PBMCs) of low- and high-stress individuals at baseline and after intervention will be assessed using an ex vivo cytotoxicity assay with human erythroleukemic cell line (K562) target cells.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of interferon-gamma
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Interferon-gamma (IFN-γ) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of tumor necrosis factors alpha and beta
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Tumor necrosis factors alpha and beta (TNF-α, TNF-β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of interleukins
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
A panel of interleukins: (IL) (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of fibroblast growth factor
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Fibroblast growth factor (FGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of granulocyte-macrophage colony-stimulating factor
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery:
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of thymus and activation-regulated chemokine
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Thymus and activation-regulated chemokine (TARC).
will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of macrophage inflammatory proteins-1 alpha and beta
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Macrophage inflammatory proteins-1 alpha and beta (MIP-1α, MIP-1β) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of macrophage-derived chemokine
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Macrophage-derived chemokine (MDC) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of monocyte chemoattractant proteins-1 and -4
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Monocyte chemoattractant proteins-1 and -4 (MCP-1, MCP-4) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of interferon gamma-induced protein-10
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Interferon gamma-induced protein-10 (IP-10) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of eotaxin and eotaxin-3
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Eotaxin and eotaxin-3 will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of C-reactive protein
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
C-reactive protein (CRP) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of intercellular adhesion molecule-1
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Intercellular adhesion molecule-1 (ICAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of placental growth factor
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Placental growth factor (PlGF) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of serum amyloid A
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Serum amyloid A (SAA) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of angiopoietin-1 receptor
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Angiopoietin-1 receptor (Tie-2) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of vascular cell adhesion molecule-1
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Vascular cell adhesion molecule-1 (VCAM-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of vascular endothelial growth factors A, C, and D
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Vascular endothelial growth factors A, C, and D (VEGF-A, VEGF-C, VEGF-D) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of vascular endothelial growth factor receptor-1
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1) will be measured before and after each intervention using the V-PLEX Human Biomarker 40-Plex Kit from Meso Scale Discovery
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change from baseline of monocyte phenotype
Zeitfenster: Baseline, 4 weeks, 8 weeks, 12 weeks
|
Classical monocytes, intermediate monocytes, and non-classical monocytes, will be identified by leukocyte common antigen (CD45+), Low-density lipoprotein receptor-related protein 1 (CD91+), cluster of differentiation 14 (CD14), cluster of differentiation 16 (CD16), and cluster of differentiation 3 (lin-CD3)/cluster of differentiation 66b (CD66b)/neural cell adhesion molecule (CD56)/cluster of differentiation 19 (CD19) using flow cytometry.
|
Baseline, 4 weeks, 8 weeks, 12 weeks
|
|
Change from baseline of monocyte functional profile
Zeitfenster: Baseline, 4 weeks, 8 weeks, 12 weeks
|
Cellular activation of classical monocytes, intermediate monocytes, and non-classical monocytes will be assessed by expression of cluster of differentiation 11b (CD11b) and cluster of differentiation 163 (CD163).
|
Baseline, 4 weeks, 8 weeks, 12 weeks
|
|
Change from baseline of natural killer cell phenotype
Zeitfenster: Baseline, 4 weeks, 8 weeks, 12 weeks
|
Natural killer (NK) cells will be identified by CD45+, cluster of differentiation 56+ (CD56+), and lin-CD3/CD66b/CD14/CD19 using flow cytometry.
|
Baseline, 4 weeks, 8 weeks, 12 weeks
|
|
Change from baseline of natural killer cell functional profile
Zeitfenster: Baseline, 4 weeks, 8 weeks, 12 weeks
|
Natural killer (NK) cell maturation status and cytotoxic potential via CD16, cluster of differentiation 57 (CD57), killer cell lectin-like receptor K1 (NKG2D), and cluster of differentiation 159 (NKG2A) will be analyzed using flow cytometry.
|
Baseline, 4 weeks, 8 weeks, 12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Changes in stool consistency
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Participants will provide stool samples at 4 times throughout the study.
Stool samples will be used to confirm the stool consistency reported by the study subject.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in stool metrics
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Participants will provide stool samples at 4 times throughout the study.
Stool samples will be used to determine the whole stool weight.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in bowel movement frequency
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
During the week prior to each intervention and the final week of each intervention, participants will maintain a stool diary for recording frequency of bowel movements.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in Gastrointestinal (GI) symptoms
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
During the week prior to each intervention and the final week of each intervention, a short GI Symptoms Questionnaire will be administered via Qualtrics to record occurrence of gastric symptoms.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in gut microbial diversity
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Participants will provide stool samples at 4 times throughout the study.
Stool samples will be used to determine the microbial community composition by 16-subunit ribosomal ribonucleic acid (16S rRNA) amplicon sequence analysis.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in stool short chain fatty acids
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Participants will provide stool samples at 4 times throughout the study.
Stool samples will be used to measure the amount of fecal short chain fatty acids (SCFAs).
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in gut inflammatory markers
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Participants will provide stool samples at 4 times throughout the study.
Stool samples will be used to measure the inflammatory marker, fecal calprotectin.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in salivary cortisol
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
To assess waking and diurnal cortisol fluctuations, saliva will be collected at home at selected times upon waking and before bedtime. The waking saliva sample must be collected within 10-15 minutes of waking. Following the waking sample, participants will be asked to collect additional saliva samples at 15, 30, 45, and 60 minutes after the waking sample, as well as a saliva sample before bedtime. In total, participants will return 24 saliva samples (6 per visit) throughout the study. |
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in urinary cortisol levels
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Before and after each intervention, 12-hour overnight urinary cortisol will be measured.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in urinary epinephrine levels
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Before and after each intervention, 12-hour overnight urinary epinephrine levels will be measured.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in urinary norepinephrine levels
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Before and after each intervention, 12-hour overnight urinary norepinephrine levels will be measured.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in urinary creatinine levels
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Before and after each intervention, 12-hour overnight urinary creatinine levels will be measured.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in resting blood pressure
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Research team will collect resting blood pressure (systolic and diastolic) in mmHg (millimeters of mercury).
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in dietary intake
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Dietary intake will be assessed by using the Automated Self-Administered 24-hour (ASA24®) dietary assessment tool, a web-based tool that enables multiple, automatically coded, self-administered 24-hour recalls.
Three dietary recalls will be conducted in the week preceding and the final week of each intervention period, for a total of 12, 24-hour dietary recalls.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in Body Weight
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Research team will collect weight in kg.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in white blood cell count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in lymphocyte count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in monocyte count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in neutrophil granulocyte count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in eosinophil count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in basophil count
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in levels of triglycerides
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in levels of total cholesterol
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in levels of HDL-cholesterol
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in levels of LDL-cholesterol
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Change in levels of glucose
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
|
Changes in gut transit time
Zeitfenster: Baseline, 4 weeks, 8 weeks, and 12 weeks
|
During the week prior to each intervention and the final week of each intervention, participants will consume a muffin containing blue food dye.
Participants will log the date and time of consumption, and will log each bowel movement until stool color changes.
This will be used to measure gut transit time.
|
Baseline, 4 weeks, 8 weeks, and 12 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Ryan Snodgrass, PhD, United States Department of Agriculture - Western Human Nutrition Research Center
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. September 2026
Primärer Abschluss (Geschätzt)
1. August 2028
Studienabschluss (Geschätzt)
1. August 2028
Studienanmeldedaten
Zuerst eingereicht
4. August 2025
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
24. Juli 2026
Zuerst gepostet (Tatsächlich)
29. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
11. September 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
8. September 2026
Zuletzt verifiziert
1. September 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2280324
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Ja
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .